ArticleJournal of thrombosis and thrombolysis2025
Atopic dermatitis, venous thromboembolism and cancer: a cohort analysis.
Article in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thrombosis in patients with cancer: challenges and advances.Journal of thrombosis and thrombolysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis is a risk factor for venous thromboembolism which may be the first manifestation of occult cancer. We examined whether a venous thromboembolism in patients with atopic dermatitis is a marker of occult cancer. We used Danish health registries to conduct this population-based cohort study. Patients with a first-time diagnosis of venous thromboembolism and a history of atopic dermatitis were identified from the Danish National Patients Registry from 1980 through 2022. We calculated the absolute risk of cancer treating death as a competing event. As a measure of relative risk, we calculated standardized incidence ratios (SIRs) for cancer among patients with venous thromboembolism and atopic dermatitis and compared the observed cancer incidence to that of the general Danish population. We identified 582 patients with a first venous thromboembolism diagnosis and a history of atopic dermatitis. During the first year of follow-up, the absolute risk of overall cancer was 1.7%, corresponding to an SIR of 2.90 (95% confidence interval [CI] 1.39-5.34). The overall SIR decreased to 1.12 (95% CI 0.74-1.62) during the subsequent years of follow-up. Although the risk estimates were imprecise, an elevated cancer risk following venous thromboembolism in patients with atopic dermatitis cannot be ruled out, particularly within the first year after venous thromboembolism, when compared to the cancer risk in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.